Cancer, Aids, and Hospice Article Archive CD from the International Journal of Pharmaceutical Compounding

Sign On

CANCER, AIDS, and HOSPICE CARE

Permanent storage and easy retrieval of Journal articles and formulations.
  - Includes the full-color, searchable, PDF files of articles and formulations from the Journal.
  - Print Journal articles in color for your research and marketing needs.
  - Eliminate long searches through past issues for articles and formulations.

CD Prices
1 = $95
2 to 5 = $85 each
6 to 9 = $75 each
10 + = $65 each

(Select Format)

This archive contains the following articles listed by volume, issue and page number:

Title (Click for Details)	Vol/Issue	Page

CANCER AND AIDS RELATED ARTICLES
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications	Vol. 22 No. 6	446
Hydroxyurea 100 mg/mL in Ora-Plus:Ora-Sweet, Ora-Plus: Ora-Sweet SF, Ora-Blend or Oral-Blend SF Oral Suspensions	Vol. 22 No. 6	496
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags	Vol. 22 No. 5	417
Calculations	Vol. 22 No. 4	314
Cinacalcet 5-mg/mL in Oral-Plus/Ora-Sweet Suspension	Vol. 22 No. 4	318
Antineoplastic Drug Contamination on the Outside of Prepared Infusion Bags	Vol. 22 No. 4	345
Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture	Vol. 22 No. 3	237
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture	Vol. 22 No. 2	151
Mercaptopurine 50 mg/mL in Ora-Sweet and Ora-Plus Suspension	Vol. 22 No. 1	51
Thalidomide 20 mg/mL in Ora-Plus and Ora-Sweet Suspension	Vol. 22 No. 1	58
Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing	Vol. 22 No. 1	60
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection	Vol. 22 No. 1	76
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride	Vol. 22 No. 1	86
Etoposide 20-mg/mL Injection	Vol. 21 No. 5	410
Tacrolimus 0.3-mg/mL Ophthalmic Solution	Vol. 21 No. 5	416
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia	Vol. 21 No. 4	347
Azathioprine 10-mg/mL Oral Suspension	Vol. 21 No. 2	146
Calculations	Vol. 21 No. 1	58
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate	Vol. 21 No. 1	66
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride	Vol. 21 No. 1	76
Erlotinib 10-mg/mL Oral Suspension	Vol. 20 No. 6	508
Imatinib 40-mg/mL Oral Suspension	Vol. 20 No. 6	510
Lapatinib Ditosylate 50-mg/mL Oral Suspension	Vol. 20 No. 6	511
Calculations	Vol. 20 No. 5	405
Tretinoin 10-mg Oral Capsules	Vol. 20 No. 4	327
Carboplatin 50-mg/mL Injection	Vol. 20 No. 3	226
Aprepitant 80-mg Capsules	Vol. 20 No. 1	48
Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date	Vol. 20 No. 1	81
Calculations	Vol. 19 No. 6	502
Cytarabine 50-mg/mL Injection	Vol. 19 No. 4	328
Tacrolimus Capsules, 0.5 mg, 1 mg, or 5 mg	Vol. 19 No. 4	333
Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes	Vol. 19 No. 4	344
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials	Vol. 19 No. 3	261
Cisplatin 1-mg/mL Injection	Vol. 19 No. 1	62
Daunorubicin 5-mg/mL Injection	Vol. 19 No. 1	63
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions	Vol. 19 No. 1	73
Leucovorin 10-mg/mL Injection	Vol. 18 No. 6	497
High-Performance Liquid Chromatographic Method Optimization for Ondansetron Assay in Extemporaneous Topical Gel and in Marketed Products	Vol. 18 No. 6	520
Roboticized Compounding of Oncology Drugs in a Hospital Pharmacy	Vol. 18 No. 5	358
Denileukin Diftitox 150-mcg/mL Injection	Vol. 18 No. 4	328
Methotrexate 2.5-mg Capsules	Vol. 18 No. 3	238
Tamoxifen 10-mg or 20-mg Capsules	Vol. 18 No. 3	240
Fludarabine Phosphate 25-mg/mL Injection	Vol. 18 No. 2	143
Secretin 4 mcg/mL Injection	Vol. 18 No. 2	148
Lomustine 100-mg Capsules	Vol. 18 No. 1	63
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2	Vol. 17 No. 6	446
Metyrosine 250-mg Capsules	Vol. 17 No. 6	506
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 1	Vol. 17 No. 5	388
Fluorouracil 50-mg/mL Injection	Vol. 17 No. 5	417
Mesna 100-mg/mL Injection	Vol. 17 No. 5	420
Methotrexate 25-mg/mL Injection	Vol. 17 No. 5	421
Dacarbazine 200-mg/mL Injection	Vol. 17 No. 4	330
Mercaptopurine 75-mg Capsules	Vol. 17 No. 3	234
PostScription: The Pharmacist's Role in the Treatment of Cancer: A Personal Plea and Testimonial	Vol. 17 No. 3	262
Dexrazoxane 1-mg/mL Injection	Vol. 17 No. 2	149
Paclitaxel 6-mg/mL Injection	Vol. 17 No. 2	151
Thiotepa 15-mg/mL Injection	Vol. 17 No. 2	152
Granisetron 1-mg/mL Injection	Vol. 17 No. 1	66
Octreotide 50-mcg/mL Injection	Vol. 17 No. 1	72
Testosterone Cypionate 100-mg/mL Injection	Vol. 17 No. 1	73
Calculations	Vol. 16 No. 6	498
Use of a Closed-system Drug Transfer Device (PhaSeal) and Impact on Preparation Time	Vol. 16 No. 5	431
Compounding of Slow-release Niacinamide Capsules: Feasibility and Characterization	Vol. 16 No. 5	434
Ondansetron Hydrochloride 2-mg/mL Injection	Vol. 16 No. 4	339
Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum	Vol. 16 No. 2	117
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration	Vol. 16 No. 1	82
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management	Vol. 16 No. 1	22
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers	Vol. 15 No. 6	458
Thioguanine 20-mg/mL Oral Suspension	Vol. 15 No. 6	506
Morphine 6-mg/mL, Haloperidol 0.5-mg/mL, and Hyoscine 6-mg/mL Infusion	Vol. 15 No. 6	504
Physiochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags	Vol. 15 No. 6	515
Granisetron Hydrochloride 0.2-mg/mL Oral Suspension	Vol. 15 No. 5	419
Study of Microbiological Safety of 25 Oncology Drugs After Multiple Uses in Aseptic Conditions	Vol. 15 No. 5	428
Methylprednisolone 4-mg/mL Oral Suspension	Vol. 15 No. 4	340
Panitumumab 2.5-mg/mL in 0.9% Sodium Chloride Injection	Vol. 14 No. 5	428
Potential Treatments for Radiation Dermatitis	Vol. 14 No. 3	210
Cyclophosphamide 10-mg/mL Oral Suspension	Vol. 14 No. 3	245
Sunitinib 10-mg/mL Oral Suspension	Vol. 14 No. 3	248
Hormonal Influences in Prostate Cancer: An Update of a Complex Subject	Vol. 14 No. 2	100
Developing a Tretinoin Oral Liquid for Patients Who Cannot Take Capsules	Vol. 14 No. 2	118
Mechlorethamine Hydrochloride 0.02% Topical	Vol. 13 No. 5	434
Myristyl Nicotinate 5% Topical Gel	Vol. 13 No. 5	435
Aprepitant 20-mg/mL Oral Liquid	Vol. 13 No. 2	153
Doxorubicin Hydrochloride 1-mg/mL in Sodium Chloride Solution Intravesical Instillation	Vol. 13 No. 2	155
Ionic Hydration Solution for Anti-Cancer Therapy	Vol. 13 No. 2	156
Compounding for Cancer in Companion Animals	Vol. 13 No. 1	42
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration	Vol. 12 No. 5	460
Compounding Challenges for Immunocompromised Patients	Vol. 12 No. 6	482
Tretinoin and Dexpanthenol Gel	Vol. 12 No. 4	361
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration	Vol. 12 No. 4	368
Cancer-Related Terminology: Glossaries for Compounding Pharmacists and Their Clients	Vol. 12 No. 1	16
Hospice and Compounding Pharmacy: Once Inseperable	Vol. 12 No. 1	28
Calculations: Compounding for Cancer Patients	Vol. 12 No. 1	62
Temozolomide 10-mg/mL Oral Liquid	Vol. 11 No. 4	336
Levorphanol for Excruciating Pain from Oral Cancer: A Case Report	Vol. 11 No. 3	212
Busulfan 2-mg/mL Oral Liquid	Vol. 11 No. 2	155
Ondansetron Hydrochloride 0.8mg/mL Oral Liquid	Vol. 11 No. 2	158
Phenoxybenzamine Hydrochloride 2-mg/mL Oral Liquid	Vol. 11 No. 2	160
Principles of Pediatric Palliative Care and Pain Control	Vol. 11 No. 1	10
Physical and Chemical Stability of Palonosetron with Metoclopramide and Promethazine During Simulated Y-Site Administration	Vol. 11 No. 1	82
Cyclophosphamide 2-mg/mL Oral Liquid	Vol. 10 No. 6	454
Dermatological Effects from Years in the Sun: Compounding Opportunities	Vol. 10 No. 5	336
Hydroxyurea 100 mg/mL	Vol. 10 No. 5	384
Indinavir 10-mg/mL Oral Liquid	Vol. 10 No. 5	385
Temozolomide Stability in Extemporaneously Compounded Oral Suspensions	Vol. 10 No. 5	396
Rifabutin 20-mg/mL Oral Liquid	Vol. 10 No. 4	305
Granisetron 0.05-mg/mL Oral Suspension	Vol. 10 No. 3	222
Mesna 20-mg/mL Syrup	Vol. 10 No. 3	224
Physical and Chemical Stability of Palonosetron Hydrochloride with Dacarbazine and with Methylprednisolone Sodium Succinate During Simulated Y-Site Administration	Vol. 10 No. 3	234
Chlorambucil 2-mg/mL Oral Liquid	Vol. 10 No. 1	59
Efavirenz 20-mg/mL Oral Liquid, Anhydrous	Vol. 10 No. 1	62
Mercaptopurine 50-mg/mL Oral Liquid	Vol. 10 No. 1	64
Thioguanine 40-mg/mL Oral Liquid	Vol. 10 No. 1	68
Dolasetron 10-mg/mL Oral Liquid	Vol. 9 No. 6	475
Brompton's Mixture	Vol. 9 No. 4	312
Physical and Chemical Stability of Palonosetron Hydrochloride with Fluorouracil and with Gemcitabine Hydrochloride during Simulated Y-site Administration	Vol. 9 No. 4	320
Compounding Antiangiogenic Cancer Therapy for Animals	Vol. 9 No. 3	195
Piroxicam 2-mg/mL Oral Liquid, Veterinary	Vol. 9 No. 3	234
Physical and Chemical Stability of Palonosetron Hydrochloride with Lorazepam and Midazolam Hydrochloride during Simulated Y-Site Administration	Vol. 9 No. 3	235
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration	Vol. 9 No. 3	238
Book and Literature Reviews	Vol. 8 No. 5	324
Acyclovir 5% and Chlorhexidine Diacetate 0.2% Topical Gel	Vol. 8 No. 5	383
Book and Literature Reviews	Vol. 8 No. 4	244
Diphenhydramine HCl 0.1%, Lidocaine HCl 1%, Misoprostol 0.0024% and Triamcinolone Acetonide 0.12% Oral Rinse	Vol. 8 No. 4	296
Glycopyrrolate 0.5-mg/mL Oral Liquid	Vol. 8 No. 3	218
Stomatitis Mouthwash	Vol. 8 No. 2	140
Tacrolimus 0.5-mg/mL Oral Liquid	Vol. 8 No. 2	141
Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared with the Use of Powder	Vol. 7 No. 5	386
ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl)	Vol. 7 No. 3	183
The Hormonal Link to Breast Cancer: The Estrogen Matrix	Vol. 6 No. 4	250
Sterilization of Talc for Use in Pleurodesis	Vol. 6 No. 2	140
Antineoplastic Agents	Vol. 5 No. 4	268
A New High-Performance Liquid Chromatographic Method for Fludarabine and Fludarabine Phosphate Compounded in Liposomes	Vol. 5 No. 4	320
Mitomycin 0.02% Ophthalmic Solution	Vol. 5 No. 3	209
Promethazine HCl 50-mg/mL in PLO Gel	Vol. 5 No. 1	51
Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome	Vol. 4 No. 5	334
Hospice and the Role of the Compounding Pharmacist	Vol. 4 No. 4	246
Nausea and Vomiting in Hospice Patients	Vol. 4 No. 4	250
Ketamine for Pain in Hospice Patients	Vol. 4 No. 4	253
Custom-Making Medications for the Hospice Patient	Vol. 4 No. 4	255
Surviving Cancer - How the Compounding Pharmacist Can Help	Vol. 4 No. 4	257
Providing Positive Outcomes through Compounding for Animal Cancer Patients	Vol. 4 No. 4	264
Dacarbazine 8-mg/mL, Doxorubicin HCl 0.8-mg/mL and Ondansetron 0.64-mg/mL injection	Vol. 4 No. 4	296
Dexamethasone 1.2%, Lorazepam 0.1%, Haloperidol 0.1%, Diphenhydramine HCl 2.4% and Metoclopramide HCl 2.4% in PLO	Vol. 4 No. 4	297
Doxorubicin HCl 0.4-mg/mL, Ondansetron HCl 0.48-mg/mL and Vincristine Sulfate 14-mcg/mL Injection	Vol. 4 No. 4	298
Misoprostol 0.0024% Mouth Rinse for Oral Ulcerations	Vol. 4 No. 4	302
Ondansetron HCl 8-mg/mL in PLO	Vol. 4 No. 4	305
Stability of 5-Fluorouracil in an Extemporaneously Compounded Ophthalmic Solution	Vol. 4 No. 4	320
Tamoxifen Citrate - A Potential Therapy for the Treatment of Keloids	Vol. 3 No. 5	380
Tamoxifen Citrate Cream 0.1%	Vol. 3 No. 5	381
Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration	Vol. 3 No. 3	241
Oral Ulceration Mouthwash	Vol. 3 No. 1	10
Five-Day Stability of Vinorelbine in 5% Dextrose Injection and in 0.9% Sodium Chloride Injection at Room Temperature	Vol. 3 No. 1	67
Minimizing the Risk of Teratogenic Substance Exposure for Pregnant Compounding Pharmacists	Vol. 2 No. 6	414
Compatibility of Paclitaxel Injection Diluent with Two Reduced-Phthalate Administration Sets for the Acclaim Pump	Vol. 2 No. 5	382
Fluorouracil 5% Topical Stick	Vol. 2 No. 4	300
Paclitaxel Compatibility with IV Express Filter Unit	Vol. 2 No. 3	243
Estrogen and Breast Cancer: Is There a Link?	Vol. 2 No. 1	21
Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux through Rabbit Rectal Membrane	Vol. 2 No. 1	83
Stability of Mechlorethamine Hydrochloride 0.01% Ointment in Aquaphor® Base	Vol. 2 No. 1	89
Compounding Pharmacists Play a Vital Role in AIDS Treatment	Vol. 1 No. 6	386
Doxorubicin HCl-Vincristine Sulfate Injection	Vol. 1 No. 5	324
Granisetron HCl-Dexamethasone Sodium Phosphate Injection	Vol. 1 No. 5	326
Metoclopramide-Lorazepam-Mannitol-Prochlorperazine Antiemetic Injection	Vol. 1 No. 5	328
Ondansetron HCl-Dexamethasone Sodium Phosphate Injection	Vol. 1 No. 5	332
Ondansetron HCl-Doxorubicin HCl-Dacarbazine Injection	Vol. 1 No. 5	333
Ondansetron HCl-Doxorubicin Sulfate-Vincristine Sulfate Injection (2 concentrations)	Vol. 1 No. 5	334
Stability of Mitomycin Aqueous Solution When Stored in Tuberculin Syringes	Vol. 1 No. 4	282
Antiemetic Injection for Cancer Chemotherapy	Vol. 1 No. 3	175
Rectal and Stomal Administration of Analgesic Suppositories	Vol. 1 No. 1	12
Aromatherapy and the Hospice Patient	Vol. 1 No. 1	18
ABH Hard Troche	Vol. 1 No. 1	26
ABH Soft Troche	Vol. 1 No. 1	27
ABH Sugar Troche	Vol. 1 No. 1	27
Antiemetic Suppositories of the Gralla Type	Vol. 1 No. 1	28
Metoclophen Nausea Suppositories	Vol. 1 No. 1	31
Metoclophen-Modified Nausea Suppositories	Vol. 1 No. 1	31
Ondansetron HCl Suppositories	Vol. 1 No. 1	34
Scopolamine Hydrobromide 0.4-mg/0.1-mL Nasal Solution	Vol. 1 No. 1	37
Scopolamine Hydrobromide 0.25-mg/0.1-mL Topical Gel	Vol. 1 No. 1	38
Compounding an Extended Stability Admixture of Paclitaxel for Long-Term Infusion	Vol. 1 No. 1	49

Title (Click for Details)	Vol/Issue	Page

HOSPICE/PALLIATIVE CARE RELATED ARTICLES
Compounded Drugs of Value in Outpatient Hospice and Palliative Care Practice	Vol. 18 No. 3	190
Palliative Care and Compounding for Household Pets	Vol. 16 No. 6	452
Compounded Oral Ketamine for Severe Depression, Anxiety, and Pain in a Hospice Patient with End-stage Chronic Obstructive Pulmonary Disease, Cardiopulmonary Failure, and Severe Renal Insufficiency: A Case Report	Vol. 16 No. 5	364
When Traditional Medicine Fails	Vol. 14 No. 1	6
Compounding for Cancer in Companion Animals	Vol. 13 No. 1	42
Topical Treatment of Neuropathic Pain	Vol. 12 No. 3	182
Hospice and Compounding Pharmacy: Once Inseperable	Vol. 12 No. 1	28
Principles of Pediatric Palliative Care and Pain Control	Vol. 11 No. 1	10
Hospice Symptom Relief Kit: An Update	Vol. 10 No. 4	288
Aseptic Compounding in New Zealand and the Use of Still Air Boxes	Vol. 10 No. 4	293
Initial Selection of Antiemetics in End-of-Life Care: A Retrospective Analysis	Vol. 10 No. 2	147
Hospice from a Compounding Pharmacist's Perspective	Vol. 10 No. 2	89
ABHR Gel in the Treatment of Nausea and Vomiting in the Hospice Patient	Vol. 10 No. 2	95
The Story of Hospice	Vol. 10 No. 2	100
The Dying Process	Vol. 10 No. 2	103
Current Topical Treatments in Wound Healing - Part 1	Vol. 8 No. 4	269
Scopolamine Hydrobromide 0.25-mg/0.1-mL Topical Gel	Vol. 8 No. 3	185
Indomethacin 50-mg Suppositories	Vol. 7 No. 5	375
ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl)	Vol. 7 No. 3	183
Hospice and the Role of the Compounding Pharmacist	Vol. 4 No. 4	246
Nausea and Vomiting in Hospice Patients	Vol. 4 No. 4	250
Ketamine for Pain in Hospice Patients	Vol. 4 No. 4	253
Custom-Making Medications for the Hospice Patient	Vol. 4 No. 4	255
Basics of Compounding: Compounding Suppositories: Part I - Theoretical Considerations	Vol. 4 No. 4	289
Dexamethasone 1.2%, Lorazepam 0.1%, Haloperidol 0.1%, Diphenhydramine HCl 2.4% and Metoclopramide HCl 2.4% in PLO	Vol. 4 No. 4	297
Managing Pain in the Terminally Ill	Vol. 2 No. 2	111
The Symptom Relief Kit for Hospice Patients	Vol. 2 No. 2	116
Compounding Pharmacists Play a Vital Role in AIDS Treatment	Vol. 1 No. 6	386
Hospice Care and the Pharmacist	Vol. 1 No. 1	11
Rectal and Stomal Administration of Analgesic Suppositories	Vol. 1 No. 1	12
Aromatherapy and the Hospice Patient	Vol. 1 No. 1	18
Aromatherapy Mood Elevation No. 1	Vol. 1 No. 1	20
Aromatherapy Mood Elevation No. 2	Vol. 1 No. 1	21
ABH Hard Troche	Vol. 1 No. 1	26
ABH Soft Troche	Vol. 1 No. 1	27
ABH Sugar Troche	Vol. 1 No. 1	27
Morphine Sulfate Slow-Release Suppositories	Vol. 1 No. 1	32
Ondansetron HCl Suppositories	Vol. 1 No. 1	34
Morphine Suppositories	Vol. 1 No. 1	36

	Instant PDF Download
	Mailed CD